MMEDF - MindMed Announces the Approval of Mescaline Study

BASEL, Switzerland, May 20, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM), a leading clinical-stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.

Mescaline is a classic serotonergic hallucinogen, similar to LSD psilocybin, with a long, non-regulated history of spiritual ...